Pre-made Sotrovimab benchmark antibody ( Whole mAb, anti-SARS-CoV-2 Spike RBD therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Sotrovimab biosimilar, Whole Mab: Anti-SARS-CoV-2 Spike RBD therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Sotrovimab is an investigational monoclonal antibody therapy medication with activity against SARS-CoV-2. It is under development by GlaxoSmithKline and Vir Biotechnology, Inc.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-530-1mg	1mg	3090	Inquiry	Inquiry

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Sotrovimab biosimilar, Whole Mab: Anti-SARS-CoV-2 Spike RBD therapeutic antibody
INN Name	Sotrovimab
Target	SARS-CoV-2 Spike RBD
Format	Whole mAb
Derivation
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Approved
Est. Status	Active
100% SI Structure	None
99% SI Structure	7jx3:AB/6ws6:EF/6wps:CD:FG:HL/6wpt:DE:HL
95-98% SI Structure	None
Year Proposed	2020
Year Recommended	na
Companies	GlaxoSmithKline;Vir Biotechnology
Conditions Approved	COVID-19
Conditions Active	na
Conditions Discontinued	na
Development Tech	na